it is a non-nucleoside reverse transcriptase inhibitor. it shows antiviral activity against wild-type HIV as well as HIV strains with mutations in reverse transcriptase. Due to no statistically-significant difference between standard triple-drug HIV therapies and the same therapy with it, its development was discontinued by the developer. 
